Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER study.
Julie E BaumanSana D KaramCathy O'BrienGabriel MakByoung Chul ChoPublished in: Head & neck (2024)
Durvalumab plus cCRT was tolerable and active in patients with unresected, locally advanced HNSCC.